Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO-- (BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study ...
Tandem Diabetes Care Inc, a leading insulin delivery and diabetes technology company, announced that the United States Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...